Theravance Biopharma to Report Third Quarter 2025 Financial Results and Host Conference Call

Strategic Insights

Oct 26, 2025 — 1 min read

Theravance Biopharma, Inc. will report its financial results for the third quarter of 2025, marking a significant milestone in the company's pursuit of delivering innovative medicines for patients with chronic diseases. The biopharmaceutical company will host a conference call and webcast on November 10, 2025, to discuss its financial performance and provide an update on its pipeline of investigational therapies. This announcement comes as the company continues to advance its late-stage investigational compound, Ampreloxetine, for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy. With a focus on creating value for its shareholders, Theravance Biopharma remains committed to its mission of developing medicines that make a difference in people's lives.

Key Takeaways:

Theravance Biopharma will report its third quarter 2025 financial results on November 10, 2025.
The company will host a conference call and simultaneous webcast at 5:00 pm EST (2:00 pm PST / 10:00 pm GMT) to discuss its financial performance and provide an update on its pipeline.
Theravance Biopharma's late-stage investigational compound, Ampreloxetine, has the potential to be a first-in-class therapy for symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
The company's focus is on delivering medicines that make a difference in people's lives, with a commitment to creating value for its shareholders.
Theravance Biopharma has already developed and commercialized the FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

Statistics:

Theravance Biopharma will distribute its third quarter 2025 financial results on November 10, 2025.
The company's conference call and webcast will take place at 5:00 pm EST (2:00 pm PST / 10:00 pm GMT) on November 10, 2025.
The webcast and conference call will be available for 30 days, until December 10, 2025.

Sources:

Theravance Biopharma, Inc. Press Release, October 27, 2025.

The End of American Hypergrowth

For two centuries, the US economy grew by adding workers. That's over.

Healthcare's $5.3 Trillion Drag

How Medical Spending Became America's Biggest Productivity Tax

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Researchers at the Wuhan University of Technology in China have made significant progress in the field of nanotechnology, specifically in the area of nanoindentation. A novel electromagnetic shock treatment (EST) method has been developed to enhance the microscale mechanical properties of a titanium alloy, with promising results obtained through array-based

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients

Research investigators at the Zhengzhou Central Hospital Affiliated to Zhengzhou University have made groundbreaking discoveries on the role of gut microbiota in determining the efficacy of immunotherapy for colon cancer patients. The study, which was recently published in Biochimica et Biophysica Acta, reveals that specific bacterial species and microbial metabolites

Read more

The End of American Hypergrowth

Healthcare's $5.3 Trillion Drag

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients